Neurocrine
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
CEOKyle W. Gano
CEOKyle W. Gano
Employees1,800
Employees1,800
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1992
Founded1992
Employees1,800
Employees1,800
NBIX Key Statistics
Market cap13.38B
Market cap13.38B
Price-Earnings ratio45.25
Price-Earnings ratio45.25
Dividend yield—
Dividend yield—
Average volume812.29K
Average volume812.29K
High today$135.45
High today$135.45
Low today$131.75
Low today$131.75
Open price$132.33
Open price$132.33
Volume611.26K
Volume611.26K
52 Week high$157.98
52 Week high$157.98
52 Week low$84.23
52 Week low$84.23
NBIX News
TipRanks 15h
Neurocrine presents one-year data from study of CrenessityNeurocrine (NBIX) Biosciences announced the presentation of new one-year data from the CAHtalyst Adult study of Crenessity showing that patients achieved lastin...
TipRanks 5d
Buy Rating for Neurocrine Biosciences Inc. Driven by Crenessity Launch and Discounted ValuationCorinne Johnson, an analyst from Goldman Sachs, has initiated a new Buy rating on Neurocrine (NBIX). Don’t Miss TipRanks’ Half-Year Sale Take advantage of Tip...
Analyst ratings
85%
of 27 ratingsBuy
85.2%
Hold
14.8%
Sell
0%
People also own
Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.